Opioid Use Disorder (OUD) Market Report 2026

The opioid use disorder (oud) market size has grown rapidly in recent years. It will grow from $4.37 billion in 2025 to $4.89 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to overprescription of opioid painkillers, increasing prevalence of chronic pain conditions, limited access to early addiction treatment, social stigma around substance abuse treatment, growth of illicit opioid availability.

The opioid use disorder (oud) market size is expected to see rapid growth in the next few years. It will grow to $7.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to rising government funding for addiction treatment programs, increasing acceptance of medication-assisted treatment, growth of online and telehealth-based addiction services, expanding insurance coverage for OUD therapies, increasing focus on preventive and harm reduction strategies. Major trends in the forecast period include rising adoption of medication-assisted treatment programs, increasing integration of behavioral therapy with pharmacological care, growing expansion of community-based opioid treatment centers, rising focus on long-acting injectable therapies for OUD, increasing emphasis on relapse prevention and long-term recovery care.

The increasing number of opioid addiction cases is expected to drive growth in the opioid use disorder (OUD) market in the coming years. Opioid addiction is a medical condition characterized by compulsive, chronic use of opioids, which can have harmful effects on the body. Opioids induce euphoria and pain relief, but prolonged use can lead to tolerance, requiring higher doses to achieve the same effect and potentially resulting in opioid use disorder. For example, in 2023, according to the Centers for Disease Control and Prevention, a US-based public health agency, there were 79,358 drug overdose deaths involving any opioid, with a rate of 23.7 deaths per 100,000 population. The growing prevalence of opioid addiction is therefore fueling the OUD market.

Leading companies in the OUD market are focusing on innovative treatments, such as next-generation extended-release buprenorphine formulations, to provide long-acting, adherence-supportive therapy that reduces withdrawal symptoms and improves recovery outcomes. Extended-release buprenorphine offers sustained medication delivery over weekly or monthly intervals, providing greater convenience and stability compared with daily oral or sublingual therapies that may increase the risk of relapse. For instance, in May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for moderate to severe OUD. Brixadi is available in two forms: a weekly injection for patients beginning treatment with a single dose of a transmucosal buprenorphine product or currently on the medication, and a monthly injection for patients already receiving treatment.

In March 2023, Indivior PLC, a US-based pharmaceutical company, acquired Opiant Pharmaceuticals Inc. for $145 million. This acquisition is expected to strengthen Indivior’s addiction treatment portfolio. Opiant Pharmaceuticals Inc., based in the U.S., develops drugs for treating opioid overdose, acute cannabinoid overdose, and opioid use disorder.

Major companies operating in the opioid use disorder (oud) market are Indivior Plc., Alkermes Inc., Braeburn Pharmaceuticals Inc., Titan Pharmaceuticals Inc., BioDelivery Sciences International Inc., Camurus AB, Orexo US Inc., Rhodes Pharmaceuticals L P, Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Mylan NV, Adapt Pharma Inc., Opiant Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd., Cipla Limited, Luye Pharma Group, Amneal Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Knight Therapeutics, BioCorRx Inc., Lannett Company Inc., Zydus Cadila, Apotex Inc., Intas Biopharmaceuticals, Glenmark Pharmaceuticals Ltd., InterveXion Therapeutics.

North America was the largest region in the opioid use disorder (OUD) market in 2025. The regions covered in the opioid use disorder (oud) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the opioid use disorder (oud) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the opioid use disorder market by increasing costs for imported active pharmaceutical ingredients, finished drug formulations, and specialized manufacturing inputs. Hospital pharmacies, retail pharmacies, and online pharmacies are most affected, particularly in north america and europe where regulatory compliance and import dependence are high. These cost pressures may impact drug pricing and availability; however, tariffs also encourage domestic drug manufacturing, supply chain localization, and investment in regional production facilities, supporting long-term market resilience.

The opioid use disorder (oud) market research report is one of a series of new reports that provides opioid use disorder (oud) market statistics, including opioid use disorder (oud) industry global market size, regional shares, competitors with a opioid use disorder (oud) market share, detailed opioid use disorder (oud) market segments, market trends and opportunities, and any further data you may need to thrive in the opioid use disorder (oud) industry. This opioid use disorder (oud) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Opioid use disorder (OUD) is a chronic brain disease caused by prolonged use of opioids, including prescription painkillers and illegal opioids. It can develop due to a combination of genetic, environmental, and behavioral factors.

The main drugs used to treat opioid use disorder include buprenorphine, naltrexone, and methadone. Buprenorphine is an opioid-class medication used to reduce cravings and withdrawal symptoms associated with opioid dependence. These medications are administered orally or parenterally and are used across various age groups, including 19-40, 41-60, and 61 and older. They are distributed through hospital pharmacies, retail pharmacies and stores, as well as online pharmacies.

The opioid use disorder (OUD) market consists of sales of bunavail, sublocade, suboxone, and zubsolv. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.